春季银行和杨梅生物制药公司宣布在慢性乙型肝炎的研究临

StephenW

Spring Bank and Arbutus Biopharma Announce Preclinical Collaboration in Study of Chronic Hepatitis B
Monday, December 19, 2016 12:00 PM UTC
Lt; / RTI & gt;
Comments

HOPKINTON, Mass., Dec. 19, 2016 - Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, and Arbutus Biopharma Corporation (NASDAQ: ABUS) today announced an agreement to perform collaborative preclinical studies in chronic hepatitis B virus (HBV) involving the co-administration of Spring Bank's SB 9200, an orally-available selective immune-modulator, and Arbutus Biopharma's AB-423, a Capsid assembly inhibitor. SB 9200 and AB-423 are each investigational compounds currently under development by the respective companies for the treatment of chronic HBV.

"The preclinical study of the combination of SB 9200 and AB-423 is the first step in evaluating how a capsid assembly inhibitor can be combined with an oral immune-modulator in the treatment of chronic HBV and potentially lead to novel combination therapeutic strategies for patients With chronic HBV, "stated Nezam Afdhal, MD, chief medical officer of Spring Bank." We look forward to working with the team at Arbutus as we advance this collaboration. "

About SB 9200

SB 9200 is Spring Bank's novel small molecule, orally-available selective immune-modulator compound being developed as both monotherapy and combination therapy as a backbone for the treatment of chronic HBV and other viral diseases. SB 9200 is currently being studied in the ACHIEVE Phase II Global trial. Part A of the ACHIEVE study is a placebo-controlled, sequential cohort, double blind trial to evaluate increased doses of SB 9200 as monotherapy for 12 weeks followed by tenofovir disoproxil fumarate 300mg (Viread® Gilead Sciences Inc.) for a further 12 weeks. Part B of the ACHIEVE study will evaluate SB 9200 in combination with tenofovir and as monotherapy versus tenofovir monotherapy after the optimal doses of SB 9200 are determined in Part A.

StephenW

春季银行和杨梅生物制药公司宣布在慢性乙型肝炎的研究临床前合作
周一，12月19，2016 12:00 UTC
Lt;或其混合物。
注释

HOPKINTON，马萨诸塞州，2016年12月19日 - Spring Bank Pharmaceuticals，Inc.（纳斯达克股票代码：SBPH），一家开发用于治疗病毒感染，癌症和炎症性疾病的新型治疗药物的临床阶段生物制药公司，以及Arbutus Biopharma公司纳斯达克股票代码：ABUS）今天宣布达成一项协议，在慢性乙型肝炎病毒（HBV）中进行协作性临床前研究，涉及共同管理Spring Bank的SB 9200（一种口服选择性免疫调节剂）和Arbutus Biopharma的AB-423装配抑制剂。 SB 9200和AB-423各自是各自公司正在开发的用于治疗慢性HBV的研究性化合物。

“SB 9200和AB-423的组合的临床前研究是评估衣壳蛋白装配抑制剂如何与口服免疫调节剂联合治疗慢性HBV并且可能导致患者新的组合治疗策略的第一步慢性HBV“，Spring Bank的首席医疗官Nezam Afdhal说，”我们期待与Arbutus的团队合作，推进这项合作。

关于SB 9200

SB 9200是Spring Bank的新型小分子，口服可用的选择性免疫调节剂化合物，作为单一疗法和联合治疗作为治疗慢性HBV和其他病毒性疾病的骨干发展。 SB 9200目前正在ACHIEVE第二阶段全球试验中进行研究。 ACHIEVE研究的A部分是安慰剂对照的顺序队列双盲试验，以评价作为单一疗法的增加剂量的SB 9200持续12周，然后是替诺福韦酯对富马酸盐300mg（吉利德科学公司（Gilead Sciences Inc.））另外12周。 ACHIEVE研究的B部分将评估SB 9200联合替诺福韦以及作为单一疗法与替诺福韦单药治疗，在部分A中确定SB 9200的最佳剂量后。

StephenW

不知SB9200和ARC520临床前研究是否还在继续?

MP4

StephenW 发表于 2016-12-20 04:27
不知SB9200和ARC520临床前研究是否还在继续?

既然杨梅也有RNAi类药，和杨梅合作杨梅也会考虑的。